TP53 and cancer: Given that metal-based chemotherapeutics, such as cisplatin and oxaliplatin are an essential part of the standard regimen for CRC treatment, our results may shed light on the anti-tumor potential of such compounds in the context of deficient or mutant p53–a common phenotype of the majority of human cancer types–What remains unclear however, is the alternative pathways leading to the regulation of p53 targets in CRC cells lacking WT p53 activity, as well as the mechanisms through which MC3 reduces p73 expression.